EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mechanism and Therapeutic Potential of Viral Mimicry in Cancer Immunotherapy

Alisha Pearl Kirkland iD, Mahek Shah iD, Charles Spruck iD

Biomolecules · 2026

DOI: 10.3390/biom16050709 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, 2026. Verfasst von Alisha Pearl Kirkland und 2 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Genome and Epigenetics Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms, Molecular Mimicry. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 241 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, United States Department of Defense, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer immunotherapy has transformed oncology by harnessing the immune system to recognize and eliminate malignant cells. However, many cancers exhibit limited or variable responses to this class of treatment due to insufficient antigen presentation and impaired interferon (IFN) signaling, creating an immunologically “cold” tumor microenvironment (TME) characterized by poor immune cell infiltration and treatment resistance. Viral mimicry has emerged as a therapeutic strategy to overcome these limitations by reactivating innate antiviral pathways within tumor cells. Viral mimicry occurs through the reactivation of endogenous retroviruses (ERVs) and other retrotransposons (e.g., LINE-1), which subsequently stimulate downstream nucleic acid sensing pathways. The resulting type I/III IFN responses restore antigen presentation and attract cytotoxic immune cells, sensitizing resistant tumors to immunotherapy. However, systemic stimulation of these pathways can trigger context-dependent inflammation and adaptive resistance, highlighting the need for temporal and spatial control. In this review, we examine the mechanistic foundation and clinical trajectory of viral mimicry, with an emphasis on its potential integration with established treatments and engineered immune cell platforms. By identifying the molecular and clinical gaps, viral mimicry can be harnessed to enhance tumor-specific immune activation and overcome treatment resistance in cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyNeoplasmsMolecular MimicryHumansAnimalsTumor MicroenvironmentEndogenous Retroviruses

Stichwörter der Autor:innen

T cellsadaptive immunitycancer immunotherapychimeric antigen receptorclinical trialsepigenetic alterationgenomic instabilityinnate immunitynatural killer cellsneoantigensrepetitive elementsviral mimicry

Autor:innen und Institutionen

  • Cancer Genome and Epigenetics Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.

ORCID-Profile: Alisha Pearl Kirkland, Mahek Shah, Charles Spruck

Förderung

  • NIH HHS
  • United States Department of Defense
  • National Institutes of Health
  • DoD PCRP

Zitieren

APA

Kirkland, A. P., Shah, M., & Spruck, C. (2026). Mechanism and Therapeutic Potential of Viral Mimicry in Cancer Immunotherapy. Biomolecules. https://doi.org/10.3390/biom16050709

Vancouver

Kirkland AP, Shah M, Spruck C. Mechanism and Therapeutic Potential of Viral Mimicry in Cancer Immunotherapy. Biomolecules. 2026. doi:10.3390/biom16050709

BibTeX
@article{Kirkland2026,
  author = {Kirkland, Alisha Pearl and Shah, Mahek and Spruck, Charles},
  title = {Mechanism and Therapeutic Potential of Viral Mimicry in Cancer Immunotherapy},
  journal = {Biomolecules},
  year = {2026},
  doi = {10.3390/biom16050709}
}
Kostenlos starten →